A Study to Evaluate the Effect of Gefapixant (AF-219/MK-7264) on Methacholine Hyper-reactivity in Participants With Asthma (MK-7264-009)

DRUG: Gefapixant 50 mg
DRUG: Gefapixant 300 mg
DRUG: Placebo to mimic 50 mg tablets
DRUG: Placebo to mimic 300 mg tablets

PHASE2

Phase

COMPLETED

Status

Enrollment

INDUSTRY

Sponsor class

Conditions

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)